InspireMD (STU:II2) Cyclically Adjusted PS Ratio: (As of Aug. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:II2 InspireMD Inc STU:II2
51 GF Score
Price €0.84
GF Value €1.47
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is InspireMD Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


InspireMD  (STU:II2) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


InspireMD Cyclically Adjusted PS Ratio Related Terms


InspireMD Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for InspireMD's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InspireMD Cyclically Adjusted PS Ratio Chart

InspireMD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.00 0.02 0.02 0.01

InspireMD Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.02 0.01 0.01 0.00

STU:II2 vs TELA, BDMD, PAVM: Cyclically Adjusted PS Ratio Comparison

For the Medical Devices subindustry, InspireMD's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InspireMD Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where InspireMD's Cyclically Adjusted PS Ratio falls into.


STU:II2
51GF Score
InspireMD Inc STU:II2
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InspireMD Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

InspireMD's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, InspireMD's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.018/333.9520*333.9520
=0.018

Current CPI (Jun. 2026) = 333.9520.

InspireMD Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.000 246.819 0.000
201712 352.500 246.524 477.512
201803 272.333 249.554 364.435
201806 95.444 251.989 126.489
201809 12.204 252.439 16.145
201812 14.176 251.233 18.843
201903 6.554 254.202 8.610
201906 13.022 256.143 16.978
201909 7.755 256.759 10.086
201912 3.494 256.974 4.541
202003 3.039 258.115 3.932
202006 0.329 257.797 0.426
202009 0.358 260.280 0.459
202012 0.040 260.474 0.051
202103 0.138 264.877 0.174
202106 0.112 271.696 0.138
202109 0.118 274.310 0.144
202112 0.157 278.802 0.188
202203 0.138 287.504 0.160
202206 0.185 296.311 0.209
202209 0.184 296.808 0.207
202212 0.121 296.797 0.136
202303 0.143 301.836 0.158
202306 0.072 305.109 0.079
202309 0.043 307.789 0.047
202312 0.048 306.746 0.052
202403 0.041 312.332 0.044
202406 0.045 314.175 0.048
202409 0.034 315.301 0.036
202412 0.038 315.605 0.040
202503 0.028 319.799 0.029
202506 0.030 322.561 0.031
202509 0.029 324.800 0.030
202512 0.033 324.054 0.034
202603 0.035 330.213 0.035
202606 0.018 333.952 0.018

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is InspireMD (STU:II2) Overvalued in 2026?

Based on GuruFocus' analysis, InspireMD stock appears to be undervalued. The current stock price of €0.84 is trading 43.2% below its estimated GF Value™ of €1.47. GuruFocus considers InspireMD to be Possible Value Trap.

Key valuation signals for STU:II2:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €1.47 vs. price of €0.84 (43.2% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InspireMD Business Description

Other Exchanges NSPR:USA
Address 6303 Waterford District Drive, Suite 215, Miami, FL, USA, 33126
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
51GF Score

Get the complete analysis for STU:II2

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.84
Price
€1.47
GF Value